Share Page:

Volume 33 , Issue 2
Spring 2019

Pages 165173

Long-term Low-Dose Sucrose May Prevent Migraine: Two Double-Blinded Randomized Controlled Pilot Trials

Ran Yan, BMSc/Xin Wang, MMSc, PhD/HaiBo Zhou, MMSc, PhD(c)/Xin Li, PhD/YanBo Diao, MMSc/YuHang Xing, MMSc/YuLan Zhu, PhD/XiaoFeng Jiang, PhD/JiaMei Sun, BMSc/ZuoMing Zhang, MMSc/YaShuang Zhao, PhD

PMID: 30726862
DOI: 10.11607/ofph.1896

Aims: To evaluate the efficacy of sucrose in the prevention of migraine attacks. Methods: Two randomized double-blinded pilot trials were conducted, one in college students and one in adults. Migraineurs were randomized into two groups that each received an oral liquid: for students, sucrose 5 g/day (s-group; n = 12) or glucose 2.5 g/day (g-group; n = 10) for 3 months; and for adults, sucrose 5 g/day (s-group; n = 10) or fructose 2.5 g/day (f-group; n = 9) for 6 months. The primary endpoint was the frequency of migraine attacks per month, and the secondary endpoints were mean duration and severity of migraine per attack. Continuous measurements were described as mean standard deviation (SD). The overall significance of the effects between different groups was tested using repeated measures analysis of variance (RANOVA), and the efficacy was evaluated using an intent-to-treat analysis. Results: Migraine frequency in the students declined significantly in the g-group (mean reduction SD: 0.65 0.71; P < .01), but not in the s-group (0.33 2.02; P = .58). RANOVA results suggested that the secondary endpoints significantly declined over time (all P < .01) with no differences between the groups. In the adult trial, mixed-effects model analysis showed that both the primary and secondary endpoints significantly declined over time with no significant differences between the groups. Conclusion: Long-term consumption of a 5-g dose of sucrose for adult migraineurs or a 2.5-g dose of glucose for college student migraineurs may be as effective as preventive treatments.

Full Text PDF File | Order Article


Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.


© 2020 Quintessence Publishing Co, Inc

Current Issue
Ahead of Print
Author Guidelines
Submission Form
Quintessence Home
Terms of Use
Privacy Policy
About Us
Contact Us